Oppenheimer analyst Mark Breidenbach maintained a Buy rating on Seres Therapeutics (NASDAQ:MCRB) on Tuesday, setting a price target of $36, which is approximately 60.28% above the present share price of $22.46.
Breidenbach expects Seres Therapeutics to post earnings per share (EPS) of -$0.39 for the second quarter of 2021.
The current consensus among 5 TipRanks analysts is for a Moderate Buy rating of shares in Seres Therapeutics, with an average price target of $37.
The analysts price targets range from a high of $46 to a low of $24.
In its latest earnings report, released on 03/31/2021, the company reported a quarterly revenue of $5.72 million and a net profit of -$35.33 million. The company's market cap is $2.06 billion.
According to TipRanks.com, Oppenheimer analyst Mark Breidenbach is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 14.1% and a 38.60% success rate.
Seres Therapeutics, Inc. operates a microbiome therapeutics platform company, which engages in the development of biological drugs. The firm creates medicines using live bacteria to treat diseases resulting from functional deficiencies in the microbiome, a condition known as dysbiosis. It focuses on implementing microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. The company was founded by Geoffrey von Maltzahn, David A. Berry and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA.